OnAir, with Clinical Respiratory News

While research has shown that women who are diagnosed and treated for OSA may experience greater improvements in quality of life scores and higher CPAP usage than men1, actually getting a diagnosis in the first place can be an uphill struggle.
So in this episode of OnAir we invite two leading experts on the topic, Prof. Sophia Schiza and Dr Alison Wimms, to explain why this is – and what can be done so more women with OSA can enjoy the benefits of therapy sooner and for longer...
They have a lot to say on the subject, so we’ve divided up the recording by questions, so you can focus on the areas that interest you the most, or listen to it as a whole – the choice is yours!:
Introduction
00:51 Schiza: Why is this an important topic?
03:09 Dr Wimms: What has kept you interested in this topic?
Differences between OSA presentation in men and women
05:02 What are the main symptoms of OSA for male and female patients?
09:06 How can we see differences in patients’ diagnostic traces?
11:51 Why do these differences exist?
11:06 Are there also difference between the sexes when it comes to treatment acceptance and response?
21:25 Are there any other differences to highlight?
Deep dive into female OSA research
27:25 Tell us more about the UK MERGE-data for mild OSA1...
33:54 ...and the ESADA-publication2 about OSA phenotypes where gender is one of the parameters of weight in the spider charts displaying patient characteristics?
Conclusion
43:31 What is the most important practical advice for clinicians who see women every day and want to help those with sleep apnoea?
Guests:
Prof. Sophia Schiza, Head of the ERS Assembly 4 Sleep Disordered Breathing and head of Sleep Disorders Center, Department of Respiratory Medicine at the School of Medicine, University of Crete, Greece
Dr Alison Wimms, Director of Medical Affairs in Clinical Research, ResMed
Hosts:
Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 
Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.
References and useful links:
Wimms AJ, Kelly JL, Turnbull CD, McMillan A, Craig SE, O'Reilly JF, Nickol AH, Decker MD, Willes LA, Calverley PMA, Benjafield AV, Stradling JR, Morrell MJ; MERGE Trial Investigators. Mild obstructive sleep apnoea in females: post hoc analysis of the MERGE randomised controlled trial. ERJ Open Res. 2024 Feb 5;10(1):00574-2023. doi: https://doi.org/10.1183/23120541.00574-2023 PMID: 38333643; PMCID: PMC10851951.
Yassen A, Coboeken K, Bailly S, Burghaus R, Buskova J, Dogas Z, Drummond M, Gouveris H, Joppa P, Lippert J, Lombardi C, Mihaicuta S, Pépin JL, Zou D, Hedner J, Grote L. Baseline clusters and the response to positive airway pressure treatment in obstructive sleep apnoea patients: longitudinal data from the European Sleep Apnea Database cohort. ERJ Open Res. 2022 Oct 31;8(4):00132-2022. doi: https://doi.org/10.1183/23120541.00132-2022 PMID: 36329798; PMCID: PMC9619251.
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Professor Ulla Møller Weinreich was provided with a nominal financial incentive for providing the following testimonial. Professor Ulla Møller Weinreich will not receive any discounts or further incentives as a result of this testimonial.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health.
© ResMed

In this episode of OnAir Professor Ulla Møller Weinreich, Head of the Danish Lung Society, explains the why, who and how of the national guidelines for home HFT her team created in 20191, including:
Why they started using home HFT and the clinical benefits they discovered, including reduced dyspnoea, easier work of breathing and improved mucus clearance, 2 and cost-effectiveness of the treatment.3
Which patients benefit the most from the treatment – and how it can ease some of the physiological strains experienced by those with COPD or bronchiectasis.
How clinicians can initiate HFT with patients, starting by defining clear indications and treatment goals, before moving on to practical considerations such as setting the right flow and choosing the right cannula.
Guest:
Professor Ulla Møller Weinreich - Head of the Respiratory Research Unit, Aalborg University Hospital, Denmark, and Head of the Danish Lung Society
Host:
Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 
References and useful links:
Storgaard LH, Hockey H, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195-1205. https://doi.org/10.2147/COPD.S159666
Weinreich, U. M., Juhl, K. S., Søby Christophersen, M., Gundestrup, S., Hanifa, M. A., Jensen, K., … Storgaard, L. H. (2023). The Danish respiratory society guideline for long-term high flow nasal cannula treatment, with or without supplementary oxygen. European Clinical Respiratory Journal, 10(1). https://doi.org/10.1080/20018525.2023.2178600
Sørensen SS, Storgaard LH, Weinreich UM. Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure. Clinicoecon Outcomes Res. 2021;13:553-564 https://doi.org/10.2147/CEOR.S312523
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Professor Ulla Møller Weinreich was provided with a nominal financial incentive for providing the following testimonial. Professor Ulla Møller Weinreich will not receive any discounts or further incentives as a result of this testimonial.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health.
© ResMed

In this episode of OnAir, host Daniela Gautschi is joined by two experts in ASV therapy* and real-world evidence: Prof. Michael Arzt (READ-ASV registry1, 2) and Prof. Renaud Tamisier (FACE-cohort3, 4 and FACIL-VAA5 registries).
Experience shows that ASV can improve symptoms and quality of life for some patients with central sleep apnoea. But which patients are most likely to benefit and why? By performing large-scale database analyses, Prof. Arzt and Prof. Tamisier have been able to identify clinically meaningful clusters of CSA patients, explore phenotypes that have yet to be studied by RCTs, and shed light on the critical role played by sleep, respiratory and cardiovascular comorbidities.
Listen now to understand how this research could transform the diagnosis, treatment and prognosis of patients with persistent CSA and Treatment-Emergent CSA.
Guests:
Prof. Michael Arzt - Professor of Internal Medicine, University Hospital Regensburg, Germany
Prof. Renaud Tamisier - Professor of Clinical Physiology, Grenoble Alpes University and Director of the Sleep Exploration Centre, Grenoble Alpes University Hospital, France
Host:
Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.
References and useful links:
Arzt M, Munt O, Pépin J-L, et al. Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV): protocol and cohort profile. ERJ Open Res 2023; 9: 00618-2022 [DOI: https://doi.org/10.1183/23120541.00618-2022]
Arzt M, Munt O, Pépin JL, Heinzer R, Kübeck R, von Hehn U, Ehrsam-Tosi D, Benjafield AV, Woehrle H. Effects of Adaptive Servo-Ventilation on Quality of Life: The READ-ASV Registry. Ann Am Thorac Soc. 2024 Jan 19. doi: https://doi.org/10.1513/AnnalsATS.202310-908OC
Tamisier R, Damy T, Bailly S FACE study investigators, et al; Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data. Thorax 2022;77:178-185. https://thorax.bmj.com/content/77/2/178
Tamisier R, Damy T, Bailly S, Goutorbe F, Davy JM, Lavergne F, Palot A, Verbraecken JA, d'Ortho MP, Pépin JL; FACE investigators; Steering committee members; d'Ortho MP, Pépin JL, Davy JM, Damy T, Tamisier R; FACE study investigators. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med. 2024 Jan;113:412-421. doi: https://doi.org/10.1016/j.sleep.2023.07.014
Observational Multicenter Cohort Study of French Patients With a Central or Combined Syndrome of Sleep Apnea With a Predominant Central SAS Treated by Adaptive Servo-Ventilation (FACIL-VAA) https://clinicaltrials.gov/study/NCT02835638
ERS workshop replay: The indication of use of ASV therapy, from evidence to clinical practice
Disclaimers:
*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.
This content is intended for health professionals only.
These testimonials are genuine and documented accounts of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenters' experiences, practices, and on recently available relevant data, which are not intended to be understood as state of the art.
Professor Michael Arzt and Professor Renaud Tamisier were provided with a nominal financial incentive for providing the following testimonial. Professor Michael Arzt and Professor Renaud Tamisier will not receive any discounts or further incentives as a result of this testimonial.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health.
© ResMed

The ATS (American Thoracic Society) International Conference is a key event in the global sleep and breathing health calendar. So in this episode of OnAir, we asked Kimberly Sterling and Luciana Rabello – who were there as part of ResMed’s Medical Affairs Team – to share the exciting developments and research findings that caught their attention.
Topics discussed include:
Endotypes: what they are and how they differ to phenotypes – with a look at the role endotyping can play in the management of heterogenous conditions like OSA, and why a collaborative approach to its application may be key.
AI in medicine: how large-language models ‘think’ about complex care cases compared to the reasoning of seasoned clinicians, and the possibility of developing speech-based screening for sleep apnoea.
GLP-1s: could the use of these anti-obesity medications be associated with increased PAP adherence?
Kimberly and Luciana also tell us about connecting with peers to share scientific findings from the 26 abstracts ResMed supported at the event – including evidence that suggests PAP therapy reduces the risks of death and hospitalisation for patients with OSA.*
Guests:
Dr Kimberly Sterling - Vice President, Global Value & Access, Medical Affairs, ResMed
Dr Luciana Rabello - Director of Clinical Advocacy, Medical Affairs, ResMed
Host:
Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 
References and useful links:
ATS President’s Message
*A. Malhotra, J.-L. Pépin, P.A. Cistulli, A. Wimms, F. Lavergne, F.H. Sert Kuniyoshi, S.H. Munson, B. Schuler, S.R. Badikol, C. Wilson, L. Willes, C. Kelly, T. Kendzerska, D.A. Johnson, R. Heinzer, C.-H. Lee, A.V. Benjafield, and on behalf of the medXcloud group. All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure Treatment (abstract). Am J Respir Crit Care Med 2024;209:A4735.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
© ResMed

Funded by a 15 million-euro grant from the EU’s Horizon 2020 programme for health demographic change and wellbeing, the Sleep Revolution project is an ambitious one that aims to shake up current diagnostic methods for sleep-disordered breathing (SBD).
In this episode of OnAir, we talk to the head of the project, Professor Erna Sif Arnardóttir. She tells us how she believes strong collaboration between the project’s partners convinced the EU that the Sleep Revolution project could make real change, including:
Bringing advanced sleep diagnostics from the hospital into patient’s homes
Encouraging patients to participate in their own care with the help of technical solutions
Developing different personalised treatment options for patients with SDB
Creating a new European Sleep Questionnaire to help capture the whole sleep profile of a person for clinical and research purposes
Prof. Arnardóttir also shares her thoughts on topics such as the importance of multi-night diagnostics, whether AHI is sufficient as parameter to classify the severity of OSA, and how digital tools – such as apps and wearables – and cooperation between different entities could transform the future of sleep medicine.
Guest:
Prof. Erna Sif Arnardóttir - Director of the Reykjavik University Sleep Institute; Associate Professor at the Department of Engineering and Department of Computer Science at Reykjavik University, Iceland
Host:
Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 
References and useful links:
https://sleeprevolution.eu/en
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Professor Erna Sif Arnardóttir was provided with a nominal financial incentive for providing the following testimonial. Professor Erna Sif Arnardóttir will not receive any discounts or further incentives as a result of this testimonial.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
© ResMed

In this episode of OnAir, sleep clinician Prof. Dr Manuel Sánchez-de-la-Torre and host Daniela Ehrsam-Tosi discuss the potential benefits of patient phenotyping for obstructive sleep apnoea.
Prof. Dr Sánchez-de-la-Torre explores why patient phenotyping can be relevant during diagnosis, for making effective treatment decisions, and during the follow-up stage. He highlights the role of patient phenotype in predicting responses and understanding neutral effects, with a particular focus on blood pressure and hypoxic burden. He also emphasises the value of telemedicine in promoting engagement and treatment adherence.
Listen to learn why progress in patient phenotyping could affect the way you treat and understand your OSA patients.
Guest:
Prof. Manuel Sánchez-de-la-Torre - University of Lleida, principal Investigator of the ‘Precision Medicine in Chronic Disease Group’ at the Biomedical Research Institute of Lleida, Spain.
Host:
Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.
Reference:
Sánchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, et al. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. JAMA. 2023;330(13):1255–1265. https://doi.org/10.1001/jama.2023.17465
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Professor Manuel Sánchez-de-la-Torre was provided with a nominal financial incentive for providing the following testimonial. Professor Manuel Sánchez-de-la-Torre will not receive any discounts or further incentives as a result of this testimonial.
© ResMed

In this episode of OnAir, clinical expert Professor Christoph Schöbel and host Daniela Ehrsam-Tosi discuss sleep quality and sleep disorders.
There’s a growing awareness of the importance of sleep for our cardiovascular system and our general health and wellbeing. At the same time, our ability to get good sleep is increasingly challenged by everything from late-night scrolling to irregular work schedules, stress and anxiety. It’s thought that 10-30% of people worldwide suffer from insomnia1, not to mention other sleep disorders like OSA and restless leg syndrome.
In this context, which diagnostic and treatment pathways should we be prioritising? Should primary care screening programmes focus on sleep as well as diet and exercise? What benefits might digital technology have to offer? Professor Schöbel shares his thoughts on these points, as well as discussing the new European Insomnia Guideline2 and the challenges of treating COMISA (co-morbid insomnia and sleep apnoea).
Guest:
Prof. Christoph Schöbel - Professor of Sleep Medicine with a focus on Telemedicine, University Medicine of Essen, Germany
Host:
Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.
References and useful links:
1. Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care. 2016 Oct-Dec;5(4):780-784. https://10.4103/2249-4863.201153. PMID: 28348990; PMCID: PMC5353813.
2. Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., Dolenc Groselj, L., Ellis, J. G., Garcia-Borreguero, D., Geoffroy, P. A., Gjerstad, M., Gonçalves, M., Hertenstein, E., Hoedlmoser, K., Hion, T., … Spiegelhalder, K. (2023). The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research, 32(6), e14035. https://doi.org/10.1111/jsr.14035
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Professor Christoph Schöbel was provided with a nominal financial incentive for providing the following testimonial. Professor Christoph Schöbel will not receive any discounts or further incentives as a result of this testimonial.
© ResMed

In this episode of OnAir, we ask whether treatment-adherent OSA patients could be lowering their cardiovascular risk while they sleep. Professor Frédéric Gagnadoux and host Nina Wiklund explore the design, results and implications of his recent 5,000-patient cohort study, which indicates that CPAP can deliver a significant reduction in major adverse cardiovascular events. They ask which patients are likely to benefit, discuss the importance of hours of usage, and consider the tools that clinicians can use to support therapy adherence. Listen to learn about the potential impact of CPAP therapy on the cardiovascular health of your OSA patients.
Guest:
Prof. Frédéric Gagnadoux - Head of the department of respiratory and sleep medicine, University Hospital of Angers, France.
Host:
Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 
References and useful links:
Gerves-Pinquie C, Bailly S, Goupil F, Pigeanne T, Launois S, Leclair-Visonneau L, et al.; Pays de la Loire Sleep Cohort Study Group. (2022). Positive airway pressure adherence, mortality and cardiovascular events in sleep apnea patients. Am J Respir Crit Care Med, 206, pp. 1393–1404. DOI: 1164/rccm.202202-0366OC
Sánchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, et al. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. 2023;330(13):1255–1265. doi:10.1001/jama.2023.17465
ERS 2023 Workshop: CPAP therapy and cardiovascular outcomes – what have we learned from real-life cohorts?
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Professor Frédéric Gagnadoux was provided with a nominal financial incentive for providing the following testimonial. Professor Frédéric Gagnadoux will not receive any discounts or further incentives as a result of this testimonial.
© ResMed

The world has changed profoundly in the 25 years since the internet became mainstream. Is it finally healthcare’s turn to experience a dramatic data-driven transformation? Daniela Ehrsam-Tosi and ResMed’s Chief Medical Officer Carlos Nunez explore the risks, realities and research potential of real-world data and deep machine learning. Their discussion starts with the perennial challenges of rising healthcare costs and ageing populations and invites us to look to a future where our data isn’t just used to serve us relevant advertising, but can also provide us with personalised healthcare in almost real time.
Guest:
Dr Carlos Nunez - Chief Medical Officer, Medical Affairs, ResMed.
Host:
Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
© ResMed

Which factors make a real difference when it comes to keeping NIV patients comfortable, motivated and well cared for at home? In this episode of the OnAir podcast, respiratory expert Dr Jean-Michel Arnal and host Nina Wiklund discuss key issues in the delivery of home NIV, with a particular focus on troubleshooting, telemonitoring and patient engagement.
As an ICU physician and the author of both a popular book1 and a recent article on home ventilation monitoring2, Dr Arnal has a deep interest and extensive experience in this field. He shares insights on using ventilator waveforms to identify common asynchronies, explains why the cycle feature is so important for patient comfort, and argues that our focus on finding data-driven predictors of exacerbation might be causing us to overlook an important low-tech solution.
Listen now for an engaging tour of key topics in home NIV that provides useful insights for NIV experts while remaining accessible to anyone looking to learn more about the subject.
Guest:
Dr Jean-Michel Arnal - Resuscitation service and ventilation unit, Hôpital Sainte-Musse, Toulon.
Host:
Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 
References:
Monitoring Mechanical Ventilation using Ventilator Waveforms, Springer: https://link.springer.com/book/10.1007/978-3-319-58655-7
Arnal J-M, Oranger M, Gonzalez-Bermejo J. Monitoring Systems in Home Ventilation. Journal of Clinical Medicine. 2023; 12(6):2163. https://doi.org/10.3390/jcm12062163
Disclaimers:
This content is intended for health professionals only.
This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
Dr Jean-Michel Arnal was provided with a nominal financial incentive for providing the following testimonial. Dr Jean-Michel Arnal will not receive any discounts or further incentives as a result of this testimonial.
Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.
© ResMed